CYCN biotech catalysts & pipeline

CYCLERION THERAPEUTICS INC · Data as of 2026-09-08

Upcoming catalysts

zagociguat — Topline data

Q4 2026

In January 2026, Tisento announced completion of enrollment in the global Phase 2b PRIZM clinical trial evaluating oral zagociguat for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS).

Source filing

CYC-126 — Initial data

2027

Initial POC clinical data from this program are currently expected in 2027.

Source filing

lead program — Initial data

in 2027

A Phase 2 proof-of-concept trial for its lead program is expected to initiate in 2026, with an initial data set anticipated in 2027.

Source filing

KRSA-028 — Initial data

mid-2027

These include the advancement of KRSA-028 through Phase 1 healthy volunteer data expected in mid-2027 and interim proof of concept data measuring amyloid plaque clearance in Alzheimer's patients expected by the end of 2027.

Source filing

KRSA-028 — Interim data

Late 2027

These include the advancement of KRSA-028 through Phase 1 healthy volunteer data expected in mid-2027 and interim proof of concept data measuring amyloid plaque clearance in Alzheimer's patients expected by the end of 2027.

Source filing

Explore the free biotech catalyst calendar